Fujisawa Healthcare Inc. Newsletter
-
Dermatitis Global Market Research Report 2023: An $8.57 Billion Market by 2027 - Long-term Forecasts to 2032
20 Mar 2023 11:17 GMT
… SA
Dow Pharm
Connetics Corporation
Fujisawa Healthcare
AbbVie Inc.
F. Hoffmann-La …
-
Inabata : Notice Regarding Officer Appointment After the Transition to a Company with Audit and Supervisory Committee
27 Apr 2022 05:29 GMT
… .
Apr. 2003
Assistanting to CEO, Fujisawa Healthcare Inc. (present Astellas US LLC …
-
Global Dermatitis Drugs Market Review 2015-2019 & Forecast to 2030 | Major Players are LEO Pharma, Novartis, Pfizer, Regeneron Pharmaceuticals & Sanofi
07 Nov 2019 11:28 GMT
… .A.
Dow Pharm
Connetics Corporation
Fujisawa Healthcare
AbbVie Inc.
F. Hoffmann-La …
-
Astellas Names Tatjana Dragovic, J.D. Head of Ethics & Compliance
28 Mar 2018 15:56 GMT
… of Law.
Wertjes joined former Fujisawa Healthcare, Inc. in November 2000 (which …
-
Atopic Dermatitis (AD) Market Analysis 2015 - 2025: Industry Analysis, Regional Analysis and Future Prospects
19 Nov 2017 12:56 GMT
… such as Elidel (Novartis), Protopic (Fujisawa Healthcare) and Desonate (Bayer Healthcare). There …
-
Astellas Announces Leadership Changes in U.S. Health Systems Commercial Organization
01 Nov 2017 22:27 GMT
… patients."
Miteff joined Astellas (Fujisawa Healthcare Inc.) in June of 2000 …
-
Atopic Dermatitis (AD) - Market Insights, Epidemiology and Market Forecast - 2025
23 Oct 2017 20:58 GMT
… such as Elidel (Novartis), Protopic (Fujisawa Healthcare) and Desonate (Bayer Healthcare). There …
-
leon-nanodrugs GmbH Starts U.S. Operations and Appoints Industry Veteran Theron (Ted) Odlaug as Chief Executive Officer
21 Sep 2015 08:36 GMT
… the senior management committee at Fujisawa Healthcare Inc. until its merger with …